Cara Therapeutics, Inc. (NASDAQ:CARA) Receives $27.84 Consensus PT from Analysts

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have been assigned a consensus rating of “Hold” from the five analysts that are currently covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold rating. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $27.84.

Separately, StockNews.com started coverage on shares of Cara Therapeutics in a report on Wednesday, January 8th. They set a “sell” rating on the stock.

Cara Therapeutics Stock Performance

Shares of CARA opened at $5.12 on Friday. Cara Therapeutics has a twelve month low of $2.71 and a twelve month high of $11.52. The firm has a market cap of $23.42 million, a P/E ratio of -0.24 and a beta of 0.50. The firm’s 50 day moving average price is $4.94 and its two-hundred day moving average price is $4.15.

Hedge Funds Weigh In On Cara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CARA. XTX Topco Ltd bought a new stake in shares of Cara Therapeutics in the third quarter valued at about $29,000. FMR LLC boosted its position in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the period. Curi RMB Capital LLC bought a new stake in shares of Cara Therapeutics in the fourth quarter valued at about $277,000. Shay Capital LLC bought a new stake in shares of Cara Therapeutics in the fourth quarter valued at about $524,000. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Cara Therapeutics in the fourth quarter valued at about $953,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.